

ENZON PHARMACEUTICALS INC

Form 8-K

May 19, 2011

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 19, 2011

ENZON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

**0-12957**

22-2372868

(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

**20 Kingsbridge Road, Piscataway, New  
Jersey**

(Address of principal executive offices)

**08854**

(Zip Code)

(732) 980-4500

(Registrant's

telephone number,

including area code)

**Not Applicable**

(Former name or

former address, if

changed since last

report)

Check the

appropriate box

below if the Form

8-K filing is

intended to

simultaneously

satisfy the filing

obligation of the

registrant under any

of the following

provisions:

Written

communications

pursuant to Rule

425 under the

Securities Act (17

CFR 230.425)

Soliciting

material pursuant to

Rule 14a-12 under

the Exchange Act

(17 CFR

240.14a-12)

Pre-commencement  
communications  
pursuant to Rule  
14d-2(b) under the  
Exchange Act (17  
CFR 240.14d-2(b))

Pre-commencement  
communications  
pursuant to Rule  
13e-4(c) under the  
Exchange Act (17  
CFR 240.13e-4(c))

---

Item 8.01 Other Events.

On May 19, 2011, Enzon Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the Company will discontinue its PEG-SN38 (EZN-2208) clinical program in this disease, following conclusion of its Phase II study.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished herewith:

Exhibit No. Description

99.1	Press Release of Enzon Pharmaceuticals, Inc. dated May 19, 2011
------	---

---

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ENZON PHARMACEUTICALS, INC.**  
(Registrant)

Date: May 19, 2011

By: /s/ Andrew Rackear

Name: Andrew Rackear

Title: Vice President and General Counsel

---

**EXHIBIT INDEX**

Exhibit No. Description

99.1	Press Release of Enzon Pharmaceuticals, Inc. dated May 19, 2011
------	---

---